A detailed history of Jacobs Levy Equity Management, Inc transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 79,359 shares of ANTX stock, worth $107,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,359
Holding current value
$107,928
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.98 - $2.96 $77,771 - $234,902
79,359 New
79,359 $84,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $26.4M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.